Sugi Predict

Sugi Predict / Compounds / SCHEMBL6797282

SCHEMBL6797282

SCHEMBL6797282

Cc1cc(O)cc(Br)c1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 6/20 0.46
▸ CHRM1 P11229 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ MAOA P21397 1/20 0.46
▸ TBXA2R P21731 1/20 0.46
▸ ADRA1A P35348 1/20 0.46
▸ HTR2B P41595 1/20 0.46
▸ ALOX5 P09917 1/20 0.41
▸ PTGS2 P35354 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.39
▸ ESR2 Q92731 3/20 0.38
▸ ESR1 P03372 2/20 0.38
▸ ACHE P22303 3/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ HSP90AA1 P07900 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ BACE1 P56817 1/20 0.35
▸ GAA P10253 1/20 0.33
▸ TDP1 Q9NUW8 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL373421 0.86 ALOX5 (0.46) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL253926 0.80 CYP3A4 (0.58) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL17659001 0.79 ALOX5 (0.52) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL27640750 0.79 CYP3A4 (0.46) CYP3A4CHRM1ALOX15MAOATBXA2R
Methane SCHEMBL27301821 0.77 CYP3A4 (0.55) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL23927494 0.75 ALOX5 (0.39) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL22265086 0.75 CYP3A4 (0.46) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL24373160 0.75 CYP3A4 (0.68) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL31618730 0.75 CYP3A4 (0.42) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL49597 0.75 CYP3A4 (0.52) CYP3A4CHRM1ALOX15MAOATBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720057-A2 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) 2026-04-08 — — EP disclosed
EP-4651955-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2025-11-26 — — EP disclosed
WO-2024249888-A2 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) 2024-12-05 — — WO disclosed
WO-2024153947-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2024-07-25 — — WO disclosed
US-20240190805-A1 PHENYLACETIC ACID DERIVATIVE, USE THEREFOR, AND PRODUCTION INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2024-06-13 — — US disclosed
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 — — CN disclosed
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 — — US disclosed
EP-4299557-A1 PHENYLACETIC ACID DERIVATIVE, USE THEREFOR, AND PRODUCTION INTERMEDIATE THEREOF Sumitomo Chemical Company Limited (JP) 2024-01-03 — — EP disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
US-10633381-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2020-04-28 — — US disclosed
US-20190144444-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2019-05-16 — — US disclosed
EP-3458445-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2019-03-27 — — EP disclosed
US-10125134-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2018-11-13 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 — — WO disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 — — WO disclosed
US-6828466-B2 Reacting arene with borane; oxidation, hydrogenation phenylboronic acid BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY 2004-12-07 — — US disclosed
US-20040030197-A1 Process for the synthesis of phenols from arenes BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY 2004-02-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190144444-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS CYP3A4 4465/4885CHRM1 4874/4885ALOX15 3532/4885
US-10633381-B2 KRas G12C inhibitors KRAS, NRAS, HRAS CYP3A4 4465/4885CHRM1 4874/4885ALOX15 3532/4885
US-10125134-B2 KRas G12C inhibitors KRAS, NRAS, HRAS CYP3A4 4465/4885CHRM1 4874/4885ALOX15 3532/4885
US-20240190805-A1 PHENYLACETIC ACID DERIVATIVE, USE THEREFOR, AND PRODUCTION INTERMEDIATE THEREOF FAR1, CYP4A11, CYP4F11 CYP3A4 63/4885CHRM1 400/4885ALOX15 198/4885
US-20240101553-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS CYP3A4 4465/4885CHRM1 4874/4885ALOX15 3532/4885
US-20180072723-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS CYP3A4 4465/4885CHRM1 4874/4885ALOX15 3532/4885
US-20040030197-A1 Process for the synthesis of phenols from arenes GRHPR, CBR1, CBR3 CYP3A4 280/4885CHRM1 2409/4885ALOX15 569/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS CYP3A4 4465/4885CHRM1 4874/4885ALOX15 3532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.